Methodology

All entries for: mAbTree Biologics AG

January 1, 2026

mAbTree Biologics AG

Orphan Drug Designation

FDA orphan drug designation: treatment of essential thrombocythemia

Disease Area: Rare Diseases
Source
Scroll to Top